The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The stock exchange (NSE) has asked Vivimed Labs to clarify two issues with its financial results for the quarter ended 31 March 2024. First, the results were not submitted in the format prescribed under Schedule III of the Companies Act, 2013. Second, the company did not submit the Statement of Modified Opinion (or a declaration of unmodified opinion) along with its results. The company's response is still awaited. This is a procedural compliance issue, not an indication of any fraud or wrongdoing.
This is a routine regulatory clarification on filing format and does not directly affect shareholders or the stock price, though delayed or non-compliant filings can attract penalties if not resolved promptly.